Exploring the Solutions for Autoimmunity
Autoimmune diseases are caused by the peripheral immune tolerance breakdown. Currently, the main methods for treating patients with autoimmune diseases and allograft recipients are non-specific immunosuppressive agents such as steroids, chemical compounds, biologics and calcineurin Inhibitors. These treatments help reduce inflammatory attacks on self-tissue, but at the same time can also induce a high risk of secondary infections and other side effects (such as osteoporosis, obesity, and chronic nephrotoxicity) in patients or recipients.
Aautoimmune diseases affect more than 50 million Americans. Three of the top six best-selling prescription drugs in 2015 were biologics used to treat autoimmune disorders . The cost of treating autoimmune disease in US is more than $ 100 billion annually.
Research & Development
Unlocking the Mysteries of Science
New Biologics for Autoimmune Diseases
RebuImmunity, LLC is a pharmaceutical entity committed to develop recombinant chimeric protein for the clinical needs. Thus far, RebuImmunity has developed a human source chimeric protein (BY-001, patent pending) with dual functions. The intramural scientific research data indicates that BY-001 is potential for a novel agent in treatment of the patients with autoimmune diseases, as well as the recipients of allografts.
Particularly, the data obtained from healthy human PBMCs (peripheral blood monocytes) allows BY-001 to complete preclinical functional demonstration in a very short period of time, and its origin in human nature makes its in vivo safety more reliable.
BY-001 is at the stage of transition from IND to NDA.
NOTES: IND = Investigational New Drug application; NDA = New Drug Application
Want to learn more about our research projects?